Does Alpha-ketoglutarate Supplementation Lower BiologicaL agE in Middle- Aged Adults?

Geroscience is an emerging interdisciplinary field of study in gerontological sciences. With emphasis on understanding the mechanistic drivers of aging, it seeks translational approaches that could eventually be applied to improve human healthspan and delay age-associated chronic diseases. Contrary to popular opinion that aging is irreversible, advances in geroscience research have demonstrated that aging is modifiable and inhibiting or activating specific molecular pathways can improve healthspan and extend lifespan in model organisms. Advocates of geroscience take the view that age-related chronic diseases are best treated by slowing the aging process, rather than using the prevailing disease-centric approach of addressing each disease alone. Thus, the concept is that biological aging, rather than chronological aging, is amenable to intervention. In this regard, geroscientists are at the forefront of longevity medicine in rigorously testing novel supplements, drugs and other prophylactics that can enhance healthspan. Some of these interventions involve repurposing existing drugs such as rapamycin, a well-known immunosuppressant, at different dosing regimens to specifically target biological hallmarks of aging. This study will investigate the effects of alpha-ketoglutarate (AKG), an endogenous metabolite, on biomarkers of aging in middle-aged residents of Singapore.

NCT Number	NCT05706389
Lead Sponsor	National University of Singapore Collaborators: AMILI Pte. Ltd., Genome Institute of Singapore
Conditions	Aging
Enrollment	120 participants
Start Date	2023-02-24
Primary Completion	2025-08-15 (estimated)
Study Completion	2027-01-15 (estimated)
Updated on ClinicalTrials.gov	2026-05-26